The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H Emara, Abeer H Abdelkader, Rasha Ibrahim Salama · 2024
Read The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study by Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H Emara, Abeer H Abdelkader, Rasha Ibrahim Salama (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616335.txt.
Description
Mohammed Gameil and co-authors weigh gallstone risk across a class of diabetes drugs, in a 2024 study. The drugs aid weight loss, and gallstones have often been seen in users. Which drug in the class carries the most risk was not clear.
The team studied about three hundred patients with type two diabetes in four groups, three on named drugs and one control group. Stones turned up in near a third of all patients and linked clearly to drug use. Most stone cases caused symptoms, and a third of those had complications. Risk ratios rose step by step across the three drugs. The results help doctors counsel patients on this side effect.
Catalog record
| CREATOR | Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H Emara, Abeer H Abdelkader, Rasha Ibrahim Salama |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |